Pemetrexed Market, by Strength (100 mg and 500 mg), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Aug 2022

Code : CMI2458

Pages :130

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

Global Pemetrexed Market: Key Developments

Various other key players have gained regulatory approval for the generic versions of pemetrexed and are expected to launch during the forecast period. Launch of generic version at low price is expected to rise adoption of the drug, which in turn will drive pemetrexed market growth over forecast period. For instance, in July 2018, the German Federal Patent Court declared the German section of European patent EP 1 313 508 for Alimta, void. Following this, in July 2018, STADAPHARM GmbH, an international pharmaceutical company, the subsidiary of STADA Arzneimittel AG launched Pemetrexed STADA generic version of Alimta in Europe. The drug is used for treating locally advanced, metastasized and non-small cell lung cancer and is a generic of the product Alimta by Lilly.
For instance, on February 3, 2022, Dr. Reddy's Laboratories Ltd., a multinational pharmaceutical company along with its subsidiaries, announced that it entered into a definitive agreement to acquire Nimbus Health GmbH, a privately owned company, Dr. Reddy's will acquire Nimbus Health for an upfront payment plus performance and milestone based earn outs over the next four years. The acquisition will allow Dr. Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a treatment option for patients.